Additional Information

Description

Halcion (triazolam) tablets, each containing 0.25 mg of the active ingredient, are prescribed for the short-term management of insomnia. Triazolam is a benzodiazepine that enhances the effects of gamma-aminobutyric acid (GABA) at its receptor sites, resulting in sedative, hypnotic, and anxiolytic effects. This mechanism helps reduce the time to fall asleep and increases the total sleep duration.

The product is packaged in unit dose cards, with each card containing 25 tablets, totaling 100 tablets per pack. This format ensures precise dosing and minimizes the risk of contamination or dosage errors. Halcion is designed for oral administration and is generally prescribed at the lowest effective dose to reduce the risk of dependence or adverse effects.

Halcion is typically well-tolerated but may cause side effects such as drowsiness, dizziness, or headache. Rarely, it may lead to more severe reactions, including complex sleep-related behaviors, memory impairment, or paradoxical excitation. Due to its potential for dependency and abuse, it is recommended for short-term use, generally not exceeding 7 to 10 consecutive days.